Dipharma

Mundipharma | February 16, 2017

Mundipharma and Helsinn Group have expanded licensing and distribution agreements for anti-emetic prophylactic agents Aloxi and Akynzeo to cover additional markets such as the Middle East, Africa, Latin America and Indonesia....

Janssen Pharmaceutica | September 06, 2017

Janssen Pharmaceutica has entered into an exclusive agreement with Mundipharma under which the latter will distribute its diabetes drugs Invokana and Vokanamet in countries in the European Economic Area (EEA) and Switzerland. Currently the deal relates to territories where the products have obtained pricing and reimbursement approvals, but additional EEA countries may be added after further agreements are in place....

Pharmaphorum Media Limited | November 27, 2018

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg. Pelmeg can now be used in Europe for patients with neutropenia and febrile neutropenia in adult cancer patients treated with chemotherapy. Pelmeg was developed by Spain’s Cinfa Biotech, which Mundipharma acquired last month, after regulators on the European Medicines Agency’s Committee f...

Pharmaceutical Technology | October 16, 2019

At the European Society of Emergency Medicine Congress, UK-based Mundipharma announced positive results from various trials of its analgesic Penthrox (methoxyflurane) for pain relief. Carried out in Italy, the MEDITA study demonstrated Penthrox was superior to standard analgesic treatment (SAT) – IV morphine for severe pain and IV paracetamol or ketoprofen for moderate trauma pain – in terms of change in pain intensity over ten minutes, the primary endpoint. Penthrox was also rated a...